Urinary Incontinence affects around 1 in 3 females.
Urinary Incontinence affects around 1 in 3 females and is the largest unmet need in female health, with limited treatment options. Patients and consumers are actively looking for a new treatment solution and Pelviva is the first clinically effective practical treatment available as a consumer healthcare solution.
This life-changing technology is a single-use disposable treatment for UI, making it easy to use, discreet and convenient for busy lifestyles. With no drug-related side effects, this multiple award-winning product is unique in a rapidly accelerating market.
Global licensing and distribution opportunities for partners provide:
- our expertise across female health in the care and pharmaceutical sectors
- a global marketing strategy
- an international hub supporting social media
- a full range of sales and marketing materials
- a highly experienced in-house regulatory team
Femeda welcomes approaches from potential corporate partners who share our innovative vision and commitment to roll out life-changing products to millions of women worldwide.
Licensing opportunities offer a unique product, brand and technology. Pelviva is CE marked in Europe (Class lla).